Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025
Business Overview: Propanc is a pre-revenue biopharmaceutical company developing PRP, a novel pancreatic proenzyme therapy designed to prevent cancer recurrence and metastasis by targeting cancer stem cells. The company holds Orphan Drug Designation for pancreatic cancer and is preparing for a Phase Ib clinical trial in Australia. Operations are primarily based in Australia with a U.S. parent entity.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(58,923,300) | $(1,820,528) |
| Operating Expenses | $57,278,131 | $1,536,049 |
| Administration Expenses | $57,027,850 | $1,253,797 |
| Research & Development | $223,721 | $248,102 |
| Cash and Cash Equivalents (End of Period) | $12,088 | $21,085 |
| Total Assets | $19,631,808 | $72,365 |
| Total Liabilities | $5,725,616 | $3,851,424 |
| Accumulated Deficit | $(125,621,520) | $(66,698,220) |
Note: The significant increase in Total Assets for 2025 is primarily driven by non-cash prepaid expenses (equity instruments issued for services) totaling approximately $19.2 million.
Material Changes vs. Prior Period
- Explosion in Administration Costs: Administration expenses surged from $1.25 million in 2024 to $57.0 million in 2025. This increase is almost entirely attributable to non-cash stock-based compensation of approximately $37.8 million for officers and employees, and $18.2 million for consulting and legal services paid in equity.
- Net Loss Expansion: Net loss increased by approximately $57.1 million year-over-year, driven by the aforementioned stock-based compensation and losses on debt extinguishment.
- Debt Extinguishment Losses: The company recorded a net loss of $871,032 on the extinguishment of debt in 2025, compared to a gain of $54,565 in 2024. This resulted from converting debt to equity at fair market values significantly higher than the debt principal.
- Derivative Liabilities: Embedded conversion option liabilities increased from $133,886 in 2024 to $403,892 in 2025 due to the issuance of new convertible notes with bifurcated conversion options.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- Clinical Timeline: The company plans to submit a Clinical Trial Application (CTA) in the second half of 2025, with approval expected in late 2025. A Phase Ib First-In-Human study is targeted to commence in the second half of 2026, with an estimated cost of $6.5 million.
- Capital Needs: Management states it does not have sufficient cash to meet obligations for the next 12 months without additional financing. The company is actively seeking equity or debt financing to fund clinical trials and operations.
Risks and Contingencies
- Going Concern: The independent auditor has issued a "Going Concern Qualification" due to the company's recurring losses, accumulated deficit, and reliance on future financing. There is substantial doubt about the company's ability to continue as a going concern for 12 months from the report date.
- Debt Defaults: As of June 30, 2025, multiple convertible notes and loans payable were in default. The company has been negotiating extensions and conversions with lenders.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including a lack of written documentation and insufficient segregation of duties.
Unusual Items
- Subsequent Equity Offering: On August 18, 2025 (post-period), the company completed a public offering of 1,000,000 shares at $4.00 per share, raising net proceeds of $3.34 million.
- Debt-for-Equity Swaps: Significant portions of debt were settled by issuing common stock at valuations far exceeding the debt principal, resulting in substantial non-cash losses.
Investor Verification Checklist
- Verify Liquidity Post-Offering: Confirm the impact of the $3.34 million August 2025 offering on the company's ability to fund the planned $6.5 million Phase Ib trial.
- Assess Stock-Based Compensation: Review the valuation methodology for the $56 million in stock-based compensation recorded in 2025 to ensure fair value assumptions are reasonable.
- Monitor Debt Status: Track the status of defaulted notes and the terms of any new financing to understand potential dilution or liquidation risks.
- Internal Control Remediation: Evaluate the progress of the company's plan to remediate material weaknesses in internal controls, specifically regarding segregation of duties.
- Clinical Milestone Feasibility: Assess the realism of the 2026 clinical trial timeline given the company's historical cash burn and funding challenges.